Skip to Content
MilliporeSigma

SML3519

Exatecan

≥98% (HPLC), topoisomerase-I inhibitor, powder

Synonym(s):

(1S,9S)-9-Ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-1-amine, DX 8951

Sign In to View Organizational & Contract Pricing.

Select a Size

5 MG

$87.10

25 MG

$298.35

$87.10


Available to ship TODAYDetails


Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C24H22FN3O4
CAS Number:
Molecular Weight:
435.45
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Exatecan, ≥98% (HPLC)

InChI

1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1

SMILES string

O=C1N2C(C3=NC4=CC(F)=C(C(CC[C@@H]5N)=C4C5=C3C2)C)=CC6=C1COC([C@@]6(CC)O)=O

InChI key

ZVYVPGLRVWUPMP-FYSMJZIKSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

Quality Level

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
SML3461C9911SML3707
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥90% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

100

Quality Level

200

Quality Level

100

storage temp.

-10 to -25°C

storage temp.

-10 to -25°C

storage temp.

2-8°C

storage temp.

-10 to -25°C

solubility

DMSO: 2 mg/mL, clear (Warmed)

solubility

DMSO: 2 mg/mL, clear (Warmed)

solubility

chloroform/methanol (4:1): 5 mg/mL

solubility

DMSO: 2 mg/mL, clear (Warmed)

color

white to beige

color

white to beige

color

-

color

white to beige

Biochem/physiol Actions

Camptothecin analog that exhibits a stronger topoisomerase-I inhibitory and antitumor activities and is highly effective against P-gp mediated MDR cells
Exatecan is a camptothecin (CPT) analog that exhibits a stronger topoisomerase-I inhibitory and antitumor activities and is highly effective against P-glycoprotein (P-gp) mediated multi-drug resistant cells. Several of the exatecan derivative based antibody-drug and peptide-drug conjugate payloads display high therapeutic indices universally across solid tumors.

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Muta. 1B - Repr. 1B

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jie Chen et al.
Molecular medicine reports, 19(1), 477-489 (2018-11-16)
Unresectable advanced pancreatic cancer (APC) is a highly lethal malignancy. Although numerous chemotherapeutic regimens are available, evidence regarding the survival extension, the life quality improvement, the associated risks and occurrence rates of adverse effects, is required. The effects of 19
N Joto et al.
International journal of cancer, 72(4), 680-686 (1997-08-07)
We previously reported that DX-8951f, a novel water-soluble camptothecin analog, significantly inhibits the growth of various human and murine tumors in vitro and in vivo. The antitumor effects and topoisomerase I inhibitory activity of DX-8951f are stronger than those of
Ghassan K Abou-Alfa et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24(27), 4441-4447 (2006-09-20)
Exatecan mesylate is a hexacyclic, water-soluble, topoisomerase-1 inhibitor. Exatecan has single-agent and combination activity with gemcitabine in advanced pancreatic cancer. A multicenter, randomized, phase III trial comparing exatecan plus gemcitabine versus gemcitabine alone in advanced pancreatic cancer was conducted. Eligibility

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service